Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilrekimig (PF-07275315) Pharmacokinetics in Healthy Chinese Adults
NCT06675188Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2025
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) and asthma comparing PF-07275315 with Placebo (2 arms). Primary endpoints: Maximum Observed Plasma Concentration at Day 181, Time to Reach Maximum Observed Plasma Concentration at Day 181 and 9 more. Started Jan 2025; status: completed.
02
Drugs
tilrekimig
03
Conditions
atopic dermatitis (AD)asthma
Beyond the preview
Go deeper on NCT06675188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06675188.